Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Parkinson's disease
pharmacokinetics
phase I
synucleinopathy
α-synuclein
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
15
03
2019
revised:
03
05
2019
accepted:
20
05
2019
pubmed:
19
6
2019
medline:
26
6
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
Pathological and genetic evidence implicates toxic effects of aggregated α-synuclein in the pathophysiology of neuronal dysfunction and degeneration in Parkinson's disease. Immunotherapy targeting aggregated α-synuclein is a promising strategy for delaying disease progression. This study (NCT02459886) evaluated the safety, tolerability, and pharmacokinetics of BIIB054, a human-derived monoclonal antibody that preferentially binds to aggregated α-synuclein, in healthy volunteers and participants with Parkinson's disease. A total of 48 healthy volunteers (age 40-65, 19 women) and 18 Parkinson's disease participants (age 47-75, 5 women, Hoehn and Yahr stage ≤2.5) were in the study. Volunteers were enrolled into 6 single-dose cohorts of BIIB054 (range 1-135 mg/kg) or placebo, administered intravenously; Parkinson's disease participants received a single dose of BIIB054 (15 or 45 mg/kg) or placebo. All participants were evaluated for 16 weeks with clinical, neuroimaging, electrocardiogram, and laboratory assessments. Serum and cerebrospinal fluid BIIB054 concentrations were measured. BIIB054/α-synuclein complexes were measured in plasma. Most adverse events were mild and assessed by investigators as unrelated to the study drug. Pharmacokinetic parameters for volunteers and the Parkinson's disease participants were similar. BIIB054 serum exposure and maximum concentrations were dose proportional during the dose range studied. In volunteers and the Parkinson's disease participants, the serum half-life of BIIB054 was 28 to 35 days; the cerebrospinal fluid-to-serum ratio ranged from 0.13% to 0.56%. The presence of BIIB054/α-synuclein complexes in plasma was confirmed; all Parkinson's disease participants showed almost complete saturation of the BIIB054/α-synuclein complex formation. BIIB054 has favorable safety, tolerability, and pharmacokinetic profiles in volunteers and Parkinson's disease participants, supporting further clinical development. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Pathological and genetic evidence implicates toxic effects of aggregated α-synuclein in the pathophysiology of neuronal dysfunction and degeneration in Parkinson's disease. Immunotherapy targeting aggregated α-synuclein is a promising strategy for delaying disease progression.
OBJECTIVE
This study (NCT02459886) evaluated the safety, tolerability, and pharmacokinetics of BIIB054, a human-derived monoclonal antibody that preferentially binds to aggregated α-synuclein, in healthy volunteers and participants with Parkinson's disease.
METHODS
A total of 48 healthy volunteers (age 40-65, 19 women) and 18 Parkinson's disease participants (age 47-75, 5 women, Hoehn and Yahr stage ≤2.5) were in the study. Volunteers were enrolled into 6 single-dose cohorts of BIIB054 (range 1-135 mg/kg) or placebo, administered intravenously; Parkinson's disease participants received a single dose of BIIB054 (15 or 45 mg/kg) or placebo. All participants were evaluated for 16 weeks with clinical, neuroimaging, electrocardiogram, and laboratory assessments. Serum and cerebrospinal fluid BIIB054 concentrations were measured. BIIB054/α-synuclein complexes were measured in plasma.
RESULTS
Most adverse events were mild and assessed by investigators as unrelated to the study drug. Pharmacokinetic parameters for volunteers and the Parkinson's disease participants were similar. BIIB054 serum exposure and maximum concentrations were dose proportional during the dose range studied. In volunteers and the Parkinson's disease participants, the serum half-life of BIIB054 was 28 to 35 days; the cerebrospinal fluid-to-serum ratio ranged from 0.13% to 0.56%. The presence of BIIB054/α-synuclein complexes in plasma was confirmed; all Parkinson's disease participants showed almost complete saturation of the BIIB054/α-synuclein complex formation.
CONCLUSIONS
BIIB054 has favorable safety, tolerability, and pharmacokinetic profiles in volunteers and Parkinson's disease participants, supporting further clinical development. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 31211448
doi: 10.1002/mds.27738
pmc: PMC6771554
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunologic Factors
0
alpha-Synuclein
0
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1154-1163Informations de copyright
© 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Références
JAMA Neurol. 2017 Feb 1;74(2):163-172
pubmed: 27918765
Mov Disord. 2018 May;33(5):684-696
pubmed: 29704272
J Neurosci. 2012 Sep 26;32(39):13454-69
pubmed: 23015436
Neurobiol Dis. 2019 Apr;124:276-288
pubmed: 30381260
Nat Rev Neurosci. 2013 Sep;14(9):626-36
pubmed: 23900411
JAMA Neurol. 2018 Jan 1;75(1):9-10
pubmed: 29131880
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Cephalalgia. 1998 Mar;18(2):97-100
pubmed: 9533606
Ann Clin Transl Neurol. 2016 Aug 28;3(10):812-818
pubmed: 27752516
AAPS J. 2017 Nov;19(6):1576-1586
pubmed: 29110222
Mov Disord. 2007 Oct 15;22(13):1901-11
pubmed: 17674410
Mov Disord. 2018 Jul;33(6):900-908
pubmed: 29570862
AAPS J. 2016 Mar;18(2):311-20
pubmed: 26821802
PLoS One. 2011 Apr 29;6(4):e19338
pubmed: 21559417
Mov Disord. 2004 Nov;19(11):1306-12
pubmed: 15390007
Neurobiol Dis. 2014 Sep;69:134-43
pubmed: 24851801
BMC Med. 2014 Jul 09;12:119
pubmed: 25012298
Clin Pharmacokinet. 2010 Oct;49(10):633-59
pubmed: 20818831
Acta Neuropathol Commun. 2018 Feb 9;6(1):7
pubmed: 29422107